Introduction
Metabolic dysfunction-associated steatohepatitis (MASH), formerly referred to as non-alcoholic steatohepatitis (NASH), represents a serious and progressive variety of fatty liver disease. The development of MASH has to do with ectopic fat accumulation into the liver (steatosis) with an inflammatory response and subsequent damage to liver cells. In the United States, MASH is believed to affect between 1.5% – 6.5% of adults, and it is anticipated that MASH will have a significantly increased prevalence in 2030. If MASH is not managed, an individual with MASH may experience progression to cirrhosis, liver failure or hepatic carcinoma.
Understanding MASH: From Silent Liver Fat to Cirrhosis Risk
MASH is part of a larger condition known as metabolic dysfunction-associated steatotic liver disease (MASLD) and is often associated with obesity, type 2 diabetes, hypertension (high blood pressure), and hyperlipidaemia (high cholesterol). Symptoms are uncommon during the early stages of MASH; however, patients may report low energy levels or mild discomfort in the upper right portion of their abdomen.
There are currently no routine screening recommendations for the detection of MASH; therefore, most patients will be diagnosed incidentally as a result of having elevated liver enzymes identified in their blood work. Diagnosing MASH typically involves performing blood tests, calculating a patient’s BMI (body mass index), and completing an ultrasound or computed tomography (CT) scan for imaging purposes, as well performing elastography to determine if there is any scarring of the liver. It is also necessary to exclude other possible causes of fatty liver besides MASH and to evaluate patients for alcoholic liver disease.
The primary treatment strategy for Nonalcoholic Fatty Liver Disease (NAFLD) involves making changes to your lifestyle. Typically, the first-line treatment for this condition is to follow an exercise regimen and eat a healthier diet, which will best help lose weight. Cutting 3–5% of body weight can dramatically improve liver fat, while cutting more than 10% of body weight can decrease fibrosis in the liver. You can achieve moderate physical activity by working out approximately 150 minutes a week. One option for obese patients is to have bariatric surgery.
As of March of 2024, the U.S. Food and Drug Administration approved the use of Rezdiffra™ (resmetirom), the first drug approved for the treatment of patients with NASH with stage two or three fibrosis (excluding cirrhosis) as part of a lifestyle modification program.
It is possible to prevent NASH through healthy eating and weight management policies like regular exercise, monitoring your diabetes as well as your cholesterol levels, severe limiting or avoiding alcohol consumption, and maintaining a regular daily exercise regimen. Additionally, do not use tobacco products.
With respect to the prognosis associated with NAFLD, up to 5–12% of patients with MASH will go on to develop cirrhosis, which can increase the chances of undergoing a liver transplant and/or developing hepatocellular carcinoma (HCC). The prognosis will depend on many individual factors, including but not limited to the patients’ genetics, the presence of any metabolic disorders or disorders, and how much liver damage has occurred at the time that the diagnosis was made.
conclusion
MASH is a silent but potentially life-threatening liver disease strongly associated with metabolic disorders. Early detection, lifestyle modification, and proper medical management are crucial to prevent progression to cirrhosis and liver cancer. With increasing global prevalence, awareness, preventive strategies, and timely intervention play a key role in improving long-term outcomes.